Can-Fite BioPharma Third Quarter 2022 Earnings: US$0.003 loss per share (vs US$0.006 loss in 3Q 2021)

Can-Fite BioPharma (TLV:CANF) Third Quarter 2022 Results

Key Financial Results

• Net loss: US$2.53m (loss narrowed by 26% from 3Q 2021).
• US$0.003 loss per share (improved from US$0.006 loss in 3Q 2021).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Can-Fite BioPharma Earnings Insights

Looking ahead, revenue is forecast to grow 57% p.a. on average during the next 3 years, compared to a 28% growth forecast for the Biotechs industry in Asia.

Performance of the market in Israel.

The company's shares are up 1.0% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Can-Fite BioPharma has 6 warning signs (and 3 which are concerning) we think you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.